SCHEMBL31023834

SCHEMBL31023834

O=C(N1CCN(C(c2ccc3c(c2)COCO3)c2ccc3c(c2)COCO3)CC1)n1nnc2ccncc21

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 11/20 0.48
▸ FAAH O00519 7/20 0.48
▸ HPGD P15428 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023844 1.00 MGLL (0.48) MGLLFAAHHPGDKMT2AALDH1A1
SCHEMBL31023866 0.93 MGLL (0.48) MGLLFAAHHPGDKMT2AALDH1A1
SCHEMBL31023681 0.88 MGLL (0.63) MGLLFAAHHPGDKMT2A
SCHEMBL31023790 0.86 MGLL (0.48) MGLLFAAH
SCHEMBL31023660 0.86 MGLL (0.48) MGLLFAAHHPGDKMT2A
SCHEMBL31023945 0.86 MGLL (0.48) MGLLFAAH
SCHEMBL31023903 0.86 MGLL (0.48) MGLLFAAHHPGDKMT2AALDH1A1
SCHEMBL31023756 0.85 MGLL (0.46) MGLLFAAHHPGDKMT2AALDH1A1
SCHEMBL31023758 0.84 MGLL (0.48) MGLLFAAHHPGDKMT2AALDH1A1
SCHEMBL31023856 0.84 MGLL (0.48) MGLLFAAHHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 — — EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL MGLL 1/4885FAAH 12/4885HPGD 1304/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL MGLL 1/4885FAAH 12/4885HPGD 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback